{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:42:11Z","timestamp":1763037731528,"version":"3.37.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"AstraZeneca"},{"name":"French PIA"},{"name":"Lorraine Universit\u00e9 d\u2019Excellence"},{"DOI":"10.13039\/501100008530","name":"FEDER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Statin treatment did not reduce the risk of cardiovascular events in haemodialysis patients in the 4D and AURORA trials. Post hoc analyses in the 4D study suggested that high cholesterol absorption was associated with increased cardiovascular risk and that atorvastatin would reduce cardiovascular risk in haemodialysis patients with low cholesterol absorption but not in those with high cholesterol absorption.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>AURORA is a randomized, double-blind, placebo-controlled, multi-centre trial in haemodialysis patients. The participants were randomly assigned to receive either rosuvastatin, 10\u2005mg daily, or a matching placebo. There was a follow-up for cardiovascular death with a median duration of 3.9 years. The cholestanol and lathosterol to cholesterol ratios were used to estimate cholesterol absorption and synthesis, respectively. Measurement of non-cholesterol sterols was available in 2332 participants of the 2733 patients included in the primary analysis of the AURORA study. A total of 598 participants died from cardiovascular diseases. The 3rd vs. the 1st tertile of the cholestanol-to-cholesterol ratio was significantly associated with increased risk of cardiovascular death [hazard ratio, HR (95% confidence interval, CI) = 1.36 (1.11\u20131.65)] in univariate (P = 0.002) and multivariate models (P = 0.034). In contrast, the 3rd vs. the 1st tertile of the lathosterol-to-cholesterol ratio was significantly associated with decreased risk of cardiovascular death [HR (95% CI) = 0.81 (0.67\u20130.99)] in univariate (P = 0.041) and multivariate (P = 0.019) models. There was no significant interaction between the cholestanol and lathosterol to cholesterol tertiles and treatment group in predicting cardiovascular death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present data from the AURORA study confirm that high cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients. Assessment of the individual cholesterol absorption rate to guide initiation of statin treatment is not supported by the findings in the AURORA study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwac059","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:15:26Z","timestamp":1649934926000},"page":"1731-1739","source":"Crossref","is-referenced-by-count":3,"title":["High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study"],"prefix":"10.1093","volume":"29","author":[{"given":"G\u00fcnther","family":"Silbernagel","sequence":"first","affiliation":[{"name":"Division of Angiology, Department of Internal Medicine, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e9vin","family":"Duarte","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT , Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Sadiku","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Fauler","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria"},{"name":"Department of Internal Medicine 5 (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Mannheim Medical Faculty, University of Heidelberg , Theodor-Kutzer-Ufer 1-3, 68167 Mannheim , Germany"},{"name":"Synlab Academy, Synlab Holding Germany GmbH, P5, 7 , 68167, Mannheim , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland E","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Erlangen , Erlangen , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G","family":"Jardine","sequence":"additional","affiliation":[{"name":"Renal Research Group, British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow , Glasgow , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad A","family":"Massy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Ambroise Par\u00e9 University Hospital, APHP, Boulogne Billancourt\/Paris, and INSERM U-1018, Centre de recherche en \u00e9pid\u00e9miologie et sant\u00e9 des populations (CESP), Equipe 5, Paris-Saclay University (PSU) and University of Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ), FCRIN INI-CRCT , Villejuif , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Centre d\u2019Investigation Clinique Plurith\u00e9mathique Pierre Drouin & D\u00e9partement de Cardiologie, Institut Lorrain du Coeur et des Vaisseaux, CHU de Nancy , Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Fellstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala University Hospital , Uppsala , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT , Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-006X","authenticated-orcid":false,"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[{"name":"Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz , Auenbruggerplatz 15, 8036 Graz , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT , Nancy , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2022101818170467600_zwac059-B1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2022101818170467600_zwac059-B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022101818170467600_zwac059-B3","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.115.018713","article-title":"Epidemiology and mechanisms of uremia-related cardiovascular disease","volume":"133","author":"Tonelli","year":"2016","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2022101818170467600_zwac059-B7","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2022101818170467600_zwac059-B8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2215\/CJN.05170511","article-title":"Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients","volume":"7","author":"Rogacev","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022101818170467600_zwac059-B9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2013.01.100","article-title":"High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis","volume":"62","author":"Silbernagel","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022101818170467600_zwac059-B10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/bmj.316.7138.1127","article-title":"Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators","volume":"316","author":"Miettinen","year":"1998","journal-title":"BMJ"},{"key":"2022101818170467600_zwac059-B11","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jacc.2015.03.551","article-title":"Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients","volume":"65","author":"Silbernagel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022101818170467600_zwac059-B12","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1194\/jlr.P002899","article-title":"The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality","volume":"51","author":"Silbernagel","year":"2010","journal-title":"J Lipid Res"},{"key":"2022101818170467600_zwac059-B13","first-page":"1275","article-title":"Results provide information about cumulative probabilities of finding significance: let\u2019s report this information","volume":"46","author":"Bliese","year":"2020","journal-title":"J Manag"},{"key":"2022101818170467600_zwac059-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"2022101818170467600_zwac059-B15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/sim.6370","article-title":"Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach","volume":"34","author":"Kang","year":"2015","journal-title":"Stat Med"},{"key":"2022101818170467600_zwac059-B16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"2022101818170467600_zwac059-B17","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2022101818170467600_zwac059-B18","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022101818170467600_zwac059-B19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacc.2006.04.081","article-title":"Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study","volume":"48","author":"Strandberg","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2022101818170467600_zwac059-B21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjcard.2021.04.023","article-title":"Triglyceride-rich lipoproteins, apolipoproteins, and atherosclerotic cardiovascular events among patients with diabetes mellitus and end-stage renal disease on hemodialysis","volume":"152","author":"Lamprea-Montealegre","year":"2021","journal-title":"Am J Cardiol"},{"key":"2022101818170467600_zwac059-B22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022101818170467600_zwac059-B23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM197712222972502","article-title":"Selective deficiency of hepatic triglyceride lipase in uremic patients","volume":"297","author":"Mordasini","year":"1977","journal-title":"N Engl J Med"},{"key":"2022101818170467600_zwac059-B24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2018.12.024","article-title":"LDL triglycerides, hepatic lipase activity, and coronary artery disease: an epidemiologic and Mendelian randomization study","volume":"282","author":"Silbernagel","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022101818170467600_zwac059-B25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1194\/jlr.P800013-JLR200","article-title":"The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease","volume":"50","author":"Silbernagel","year":"2009","journal-title":"J Lipid Res"},{"key":"2022101818170467600_zwac059-B26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2008.11.146","article-title":"The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure","volume":"141","author":"P\u00e9rez A","year":"2010","journal-title":"Int J Cardiol"},{"key":"2022101818170467600_zwac059-B27","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1194\/jlr.P088583","article-title":"The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption","volume":"60","author":"Silbernagel","year":"2019","journal-title":"J Lipid Res"},{"key":"2022101818170467600_zwac059-B29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/0886022X.2016.1256309","article-title":"Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients","volume":"39","author":"Tian","year":"2017","journal-title":"Ren Fail"},{"key":"2022101818170467600_zwac059-B30","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2215\/CJN.09121010","article-title":"Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis","volume":"6","author":"M\u00e4rz","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022101818170467600_zwac059-B31","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/2047487320905721","article-title":"A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis","volume":"28","author":"Genser","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2022101818170467600_zwac059-B32","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1161\/CIR.0000000000000743","article-title":"Dietary cholesterol and cardiovascular risk: a science advisory from the American Heart Association","volume":"141","author":"Carson","year":"2020","journal-title":"Circulation"},{"key":"2022101818170467600_zwac059-B33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-2275(20)38146-3","article-title":"Further validation of the plasma isotope ratio method for measurement of cholesterol absorption in man","volume":"23","author":"Samuel","year":"1982","journal-title":"J Lipid Res"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/13\/1731\/46562725\/zwac059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwac059\/43683432\/zwac059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/13\/1731\/46562725\/zwac059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T18:19:12Z","timestamp":1666117152000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/13\/1731\/6580396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":33,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,5,4]]},"published-print":{"date-parts":[[2022,10,18]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwac059","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"type":"print","value":"2047-4873"},{"type":"electronic","value":"2047-4881"}],"subject":[],"published-other":{"date-parts":[[2022,9,13]]},"published":{"date-parts":[[2022,5,4]]}}}